KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Effect of home-based prehabilitation on postoperative complications after surgery for gastric cancer: randomized clinical trial. PMID 37750588 · Br J Surg · 2023-Nov-09 The record describes an RCT of prehabilitation for gastric cancer patients undergoing surgery, with some receiving neoadjuvant chemotherapy. While it is an oncology trial with a drug intervention component, the primary and key secondary endpoints are postoperative complications and other non-time-to-event outcomes. No time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or corresponding analysis (Kaplan-Meier, HR) is reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Anti-Cancer Activity of the Naturally Occurring Dipeptide Carnosine: Potential for Breast Cancer. PMID 37998326 · Cells · 2023-Nov-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A Whole-Food, Plant-Based Randomized Controlled Trial in Metastatic Breast Cancer: Weight, Cardiometabolic, and Hormonal Outcome. PMID 37986940 · Res Sq · 2023-Nov-08 The record describes a randomized controlled trial in metastatic breast cancer with a dietary intervention and systemic therapy. However, it is not a Phase III/IIIb or Phase II/III trial, and the primary endpoints are cardiometabolic/hormonal parameters and weight, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The 'cancer progression markers' (CA 15-3, etc.) are continuous lab values, not time-to-event outcomes. Therefore, it does not meet the inclusion criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes. PMID 37940157 · BMJ Open · 2023-Nov-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations. PMID 37937645 · JCI Insight · 2023-Nov-08 The study is a Phase III trial of a drug (sirolimus) in humans and reports original results. However, it is excluded because the condition treated (slow-flow vascular malformations) is not a human malignant neoplasm, and the primary efficacy endpoint is clinical improvement, not a time-to-event outcome like OS, PFS, or DFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
MILACC study: could undetected lymph node micrometastases have impacted recurrence rate in the LACC trial? PMID 37652529 · Int J Gynecol Cancer · 2023-Nov-06 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Life quality improvement of patients with non-small cell lung cancer undergoing targeted therapy: A case study of continuous care. PMID 37932985 · Medicine (Baltimore) · 2023-Nov-03 The study is a randomized controlled trial in oncology with time-to-event endpoints and a drug intervention. However, the primary focus and reported outcome is on life quality improvement (QoL scales, compliance, adverse reactions), making the report type 'quality_of_life'. The primary efficacy endpoint is not the focus; thus, it does not meet the requirement for a primary/key time-to-event efficacy endpoint report. Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial). PMID 37923987 · BMC Cancer · 2023-Nov-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care. PMID 37922883 · Am J Hum Genet · 2023-Nov-02 The record describes a pragmatic RCT protocol for implementing polygenic risk scores in primary care. It is an oncology-related human randomized trial, but it lacks a Phase III/IIIb designation, involves no drug intervention (only a genetic test), does not report time-to-event efficacy endpoints (OS, PFS, DFS, etc.) for a cancer, and presents no results (protocol only).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial. PMID 37919269 · Nat Commun · 2023-Nov-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. PMID 37870974 · N Engl J Med · 2023-Nov-02 The record describes a Phase III randomized controlled trial with a drug intervention (durvalumab) and a primary time-to-event endpoint (EFS), meeting all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. PMID 37506339 · Blood · 2023-Nov-02 Record meets all eligibility criteria: Phase III randomized oncology trial with drug intervention and primary time-to-event efficacy endpoint (PFS).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
RESTART trial design: two-stage seamless transition design with operational considerations. PMID 36653753 · J Biopharm Stat · 2023-Nov-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma. PMID 37824758 · Blood Cancer Discov · 2023-Nov-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Robotic versus open surgery for simultaneous resection of rectal cancer and liver metastases: a randomized controlled trial. PMID 37800563 · Int J Surg · 2023-Nov-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial. PMID 37768670 · JAMA Oncol · 2023-Nov-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial. PMID 37756582 · Cancer Prev Res (Phila) · 2023-Nov-01 The record is an original report from a randomized trial, but it is a subgroup analysis focused on genetic polymorphisms, and the primary endpoint (polyp recurrence risk) is not a time-to-event endpoint as defined by the cohort criteria (OS, PFS, DFS, etc., with Kaplan-Meier or HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. PMID 37707791 · Cancer Discov · 2023-Nov-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). PMID 37651261 · Clin Cancer Res · 2023-Nov-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial. PMID 37607321 · J Clin Oncol · 2023-Nov-01 Meets all eligibility criteria: oncology (breast cancer), human, randomized, Phase III, time-to-event primary endpoint (DFS), drug intervention (tamoxifen ± OFS), and original trial results with reported hazard ratios and Kaplan-Meier survival rates.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Erratum to: Caudell JJ, Torres-Saavedra PA, Rosenthal DI, Axelrod RS, et al. Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2023;116:533-543. PMID 37578414 · Int J Radiat Oncol Biol Phys · 2023-Nov-01 The record is a published erratum to a primary trial report. The title references a 'Long-Term Update' of a Phase 3 randomized trial, but the metadata indicates it is an 'Erratum' and lacks any abstract, mesh terms, or keywords to establish the presence of a primary/time-to-event efficacy endpoint (OS, PFS, etc.) in this specific document. Therefore, it cannot be considered an original formal-result report of the trial.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study. PMID 37531592 · J Clin Oncol · 2023-Nov-01 The record is an original result of a randomized drug trial with oncology, human, and time-to-event endpoints. However, the explicit Phase III/IIIb or Phase II/III designation is not clearly established in the provided metadata or abstract. The trial is described as a 'protocol study' and uses a '2015 Protocol,' but the phase is not explicitly stated as Phase III. Therefore, the phase criterion cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: a randomized controlled trial. PMID 37526089 · Int J Surg · 2023-Nov-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. PMID 37523624 · J Clin Oncol · 2023-Nov-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A Randomized Feasibility Trial of Stereotactic Prostate Radiation Therapy With or Without Elective Nodal Irradiation in High-Risk Localized Prostate Cancer (SPORT Trial). PMID 36893820 · Int J Radiat Oncol Biol Phys · 2023-Nov-01 The record describes a randomized feasibility trial (Phase II level) of a radiation therapy intervention (not a drug) with primary endpoints focused on feasibility and toxicity, not on a time-to-event efficacy outcome. It therefore fails to meet the criteria for a Phase III/IIIb drug-intervention randomized trial with a time-to-event primary/key secondary endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preliminary results of randomized phase II study of etoposide plus lobaplatin or etoposide plus cisplatin with concurrent thoracic radiotherapy in the treatment of limited-stage small cell lung cancer. PMID 36727741 · Anticancer Drugs · 2023-Nov-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial. PMID 38106561 · EClinicalMedicine · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine on Postoperative Patients with Non-Muscle Invasive Bladder Cancer and Its Influence on Serum-Related Factors. PMID 38053420 · Arch Esp Urol · 2023-Nov The study is a randomized controlled trial in oncology with a drug intervention and reports original results. However, the phase is not explicitly stated in the provided metadata (phase3_or_definitive: null), and the primary/time-to-event endpoint is not identified; outcomes reported are serum-related factors, immune function, recurrence rate, and safety, not OS/PFS/DFS/etc. with Kaplan-Meier or HR. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Sunvozertinib: First Approval. PMID 37962831 · Drugs · 2023-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial. PMID 37945748 · Oncogene · 2023-Nov The record describes a secondary analysis validating a new biomarker test using existing trial data, not an original formal-result report of the randomized trial's efficacy endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Phase II multicenter trial: first-line immunochemotherapy with or without radiotherapy in metastatic esophageal squamous cell cancer (SCR-ESCC-01). PMID 37937444 · Future Oncol · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study. PMID 37935428 · Cancer Med · 2023-Nov Study is a randomized, double-blind, Phase III oncology trial with a drug intervention and original results, but the primary efficacy endpoint is Overall Response Rate (ORR), which is not a time-to-event endpoint. No time-to-event endpoint (e.g., OS, PFS, DFS) is reported or indicated as a primary or key secondary endpoint in the provided abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. PMID 37935109 · J Natl Compr Canc Netw · 2023-Nov The record describes a secondary analysis of a Phase III randomized trial evaluating a predictive biomarker for chemotherapy-induced peripheral neuropathy (a toxicity endpoint). While the underlying trial is eligible, this specific report focuses on a safety/toxicity endpoint (grade ≥3 CIPN) and does not present a primary or key secondary time-to-event efficacy outcome (e.g., OS, PFS, DFS) with Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the criteria for a KM digitization cohort of efficacy endpoints.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette-Guérin versus BCG alone in non-muscle-invasive bladder cancer: A randomized controlled trial. PMID 37932566 · Investig Clin Urol · 2023-Nov The study is a randomized controlled trial in oncology with a drug intervention, but it does not present a time-to-event efficacy endpoint (e.g., Kaplan-Meier curves, hazard ratios for OS, PFS, DFS, etc.) as required. The endpoints are reported as percentages at specific time points. Additionally, the trial phase is not explicitly stated as Phase III or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer: YCOG1402 (SOAP trial). PMID 37927922 · Ann Gastroenterol Surg · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[Systemic therapies for advanced thyroid cancer - an update]. PMID 37918424 · Dtsch Med Wochenschr · 2023-Nov The record is a review article summarizing the landscape and approvals based on trials, not an original report of a single Phase III/IIIb or Phase II/III randomized trial with a primary or key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. PMID 37914483 · Lancet Haematol · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Modifiable fall risk factors among older adults with advanced cancer: Secondary analysis of a cluster-randomized clinical trial. PMID 37897888 · J Geriatr Oncol · 2023-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. PMID 37875771 · Target Oncol · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer. PMID 37839313 · Gynecol Oncol · 2023-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation. PMID 37837921 · J Infect Public Health · 2023-Nov The trial is randomized and has drug interventions (antiviral agents) and time-to-event endpoints, but it is not a Phase III/IIIb or Phase II/III trial of a malignant neoplasm. The primary efficacy analysis focuses on hepatitis B relapse rates, which is a non-oncological outcome. Therefore, it does not meet the criterion for a drug-containing intervention trial with a primary/key secondary time-to-event efficacy endpoint for a human malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HPV testing versus p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: results from the DAHANCA 19 study. PMID 37837201 · Acta Oncol · 2023-Nov While the record is from a randomized, oncology, human trial with time-to-event endpoints and a drug intervention, the specific trial phase (Phase III/IIIb or Phase II/III) is not explicitly confirmed in the provided text. Furthermore, this particular report appears to be a biomarker/prognostic analysis within the trial, not the primary efficacy report for a specific drug intervention, which is a core eligibility requirement.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Microvascular invasion-negative hepatocellular carcinoma: Prognostic value of qualitative and quantitative Gd-EOB-DTPA MRI analysis. PMID 37832198 · Eur J Radiol · 2023-Nov The study is a retrospective prognostic model analysis using MRI for HCC, not a randomized controlled trial evaluating a drug intervention. While it reports time-to-event outcomes (recurrence-free survival) with Kaplan-Meier analysis and is an original result, it lacks the essential criteria of a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy. PMID 37827064 · Eur J Cancer · 2023-Nov The record is a cross-sectional methodological study examining statistical practices (the 'Table 1 Fallacy') across many phase III oncology trials, not a report of a specific trial's results with a drug intervention and time-to-event endpoint. Therefore, it does not meet eligibility criteria.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adherence to a Mediterranean diet may improve serum adiponectin in adults with nonalcoholic fatty liver disease: The MEDINA randomized controlled trial. PMID 37801761 · Nutr Res · 2023-Nov Study is a randomized controlled trial in humans, but it is not an oncology study, lacks a drug intervention, and does not report a time-to-event efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis. PMID 37801281 · Dermatol Ther (Heidelb) · 2023-Nov The study is a network meta-analysis summarizing efficacy of deucravacitinib for plaque psoriasis, not oncology, and does not report time-to-event endpoints like OS or PFS.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and validation of a nomogram based on preoperative variables for predicting recurrence-free survival in stage IA lung adenocarcinoma. PMID 37793977 · Thorac Cancer · 2023-Nov The record describes a retrospective biomarker validation study for predicting recurrence-free survival in early-stage lung adenocarcinoma. It meets oncology, human, randomized (cohort split), and time-to-event criteria. However, it fails on two key inclusion criteria: 1) It lacks a drug-containing intervention (it compares surgical approaches guided by a nomogram, not a drug), and 2) It is not a Phase III/IIIb or Phase II/III randomized trial of a therapeutic agent.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer. PMID 37792130 · Eur J Drug Metab Pharmacokinet · 2023-Nov The report is a valid Phase III randomized trial of a drug intervention in oncology, but it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with associated Kaplan-Meier or HR analysis as a primary or key secondary outcome. The study's primary analysis is pharmacokinetic similarity, which does not meet the criteria for inclusion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endobronchial ultrasound in diagnosing and staging of lung cancer by Acquire 22G TBNB versus regular 22G TBNA needles: A randomized clinical trial. PMID 37757575 · Lung Cancer · 2023-Nov The study is a randomized, multicenter clinical trial in human lung cancer, reporting primary results. However, it is excluded because: 1) The phase is not specified as Phase III/IIIb or Phase II/III (the trial is described as a 'randomized clinical trial' without a definitive phase designation). 2) The primary outcome is PD-L1 suitability rate, which is a diagnostic/pathological endpoint, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. No Kaplan-Meier curves or hazard ratios are reported. 3) The intervention compares two diagnostic needles (medical devices), not a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. PMID 37752892 · Curr Med Res Opin · 2023-Nov The study is an oncology Phase III randomized trial with a drug intervention, but the reported analysis is explicitly a health-related quality of life (HRQoL) and patient-reported outcomes (PRO) analysis. It does not report on the required primary or key secondary time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR for such endpoints). Therefore, it is excluded based on endpoint type.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -